The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
Patrick Temi Adegun1, Philip Babatunde Adebayo2, Samuel Adeniran Atiba3
1 Department of Surgery, College of Medicine, Ekiti State University, Ado-Ekiti, Ekiti State, Nigeria;
2 Department of Medicine, Ladoke Akintola University of Technology, Ogbomoso, Nigeria;
3 Department of Chemical Pathology, College of Medicine, Ekiti State University, Ado-Ekiti, Ekiti State, Nigeria
The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS
Patrick Temi Adegun1, Philip Babatunde Adebayo2, Samuel Adeniran Atiba3
1 Department of Surgery, College of Medicine, Ekiti State University, Ado-Ekiti, Ekiti State, Nigeria;
2 Department of Medicine, Ladoke Akintola University of Technology, Ogbomoso, Nigeria;
3 Department of Chemical Pathology, College of Medicine, Ekiti State University, Ado-Ekiti, Ekiti State, Nigeria
摘要 Objective: This study was undertaken to determine the likelihood of having serum total prostate specific antigen (PSA) levels ≥4.0 ng/mL and ≥10.0 ng/mL among a cohort of non-obese and obese Nigerian men with lower urinary tract symptoms (LUTS). Methods: This was a prospective cross-sectional survey among men who presented with benign prostatic hypertrophy to the urology clinic of the Ekiti State University Teaching Hospital, Ado -Ekiti with LUTS between January 1 and December 31, 2014. One hundred and forty men who presented in the urologic clinic with LUTS were recruited. PSA was analyzed using standard method while other clinical variables were collected using a clinical case form. Multivariate logistic regression was used to estimate the odds of an abnormal PSA of ≥4.0 ng/mL or ≥10.0 ng/mL in these men. Results: The mean ages of obese and non-obese men were 64.8 and 64.0 years respectively. The mean total serum PSA were 14.8 and 13.2 ng/mL for obese and non-obese men respectively. Univariate analysis showed no difference (p > 0.05) in the proportion of obese and non-obese men with LUTS who had a PSA threshold of at least ≥4.0 ng/mL. Multivariate logistic regression showed that, at a PSA threshold of 10.0 ng/mL, obese men had a statistically significant proportion (p < 0.05). Although not significant, non-obese patients were less likely to have PSA level of ≥4.0 ng/mL (OR 0.701; 95% CI 0.301-1.630) compared to obese men. In the same vein, non-obese men were less likely to have a PSA level of 10.0 ng/mL (OR, 0.686; 95% CI, 0.318-8.478) in a simultaneous context of age. Conclusion: Our study demonstrated that, in a sample population of predominantly native African men, there was a non-significantly higher likelihood of overweight/obese patients having a higher serum PSA level than the non-obese. A community based study is needed to further confirm this finding.
Abstract: Objective: This study was undertaken to determine the likelihood of having serum total prostate specific antigen (PSA) levels ≥4.0 ng/mL and ≥10.0 ng/mL among a cohort of non-obese and obese Nigerian men with lower urinary tract symptoms (LUTS). Methods: This was a prospective cross-sectional survey among men who presented with benign prostatic hypertrophy to the urology clinic of the Ekiti State University Teaching Hospital, Ado -Ekiti with LUTS between January 1 and December 31, 2014. One hundred and forty men who presented in the urologic clinic with LUTS were recruited. PSA was analyzed using standard method while other clinical variables were collected using a clinical case form. Multivariate logistic regression was used to estimate the odds of an abnormal PSA of ≥4.0 ng/mL or ≥10.0 ng/mL in these men. Results: The mean ages of obese and non-obese men were 64.8 and 64.0 years respectively. The mean total serum PSA were 14.8 and 13.2 ng/mL for obese and non-obese men respectively. Univariate analysis showed no difference (p > 0.05) in the proportion of obese and non-obese men with LUTS who had a PSA threshold of at least ≥4.0 ng/mL. Multivariate logistic regression showed that, at a PSA threshold of 10.0 ng/mL, obese men had a statistically significant proportion (p < 0.05). Although not significant, non-obese patients were less likely to have PSA level of ≥4.0 ng/mL (OR 0.701; 95% CI 0.301-1.630) compared to obese men. In the same vein, non-obese men were less likely to have a PSA level of 10.0 ng/mL (OR, 0.686; 95% CI, 0.318-8.478) in a simultaneous context of age. Conclusion: Our study demonstrated that, in a sample population of predominantly native African men, there was a non-significantly higher likelihood of overweight/obese patients having a higher serum PSA level than the non-obese. A community based study is needed to further confirm this finding.
通讯作者:
Patrick Temi Adegun
E-mail: patrickikelomo@yahoo.com
引用本文:
Patrick Temi Adegun, Philip Babatunde Adebayo, Samuel Adeniran Atiba. The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS[J]. Asian Journal of Urology, 2015, 2(3): 158-162.
Patrick Temi Adegun, Philip Babatunde Adebayo, Samuel Adeniran Atiba. The likelihood of having serum level of PSA of ≥4.0 ng/mL and ≥10.0 ng/mL in non-obese and obese Nigerian men with LUTS. Asian Journal of Urology, 2015, 2(3): 158-162.
Chia SE, Lau WK, Chin CM, Tan J, Ho SH, Lee J, et al. Effect of ageing and body mass index on prostate-specific antigen levels among Chinese men in Singapore from a community-based study. BJU Int 2009;103:1487-71.
[2]
Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
[3]
Oesterling JE. Prostate specific antigen:a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991;145:907-73.
[4]
Consedine NS, Morgenstern AH, Kudadjie-Gyamfi E, Magai C. Neugut AI. Prostate cancer screening behavior in men from seven ethnic groups:the fear factor. Cancer Epidemiol Biomarkers Prev 2006;15:228-87.
[5]
Banez LL, Hamilton RJ, Partin AW. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007;298:2275-50.
[6]
Kubota Y, Seike K, Maeda S. Relationship between prostatespecific antigen and obesity in prostate cancer screening:analysis of a large cohort in Japan. Int J Urol 2011;18:72-2.
[7]
Grubb III RL, Balck A, Izmirlian G. Serum prostate-specific antigen hemodilution among obese men undergoing screening in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev 2009;18:748-81.
[8]
Wright JL, Lin DW, Stanford JL. The effect demographic and clinical factors on the relationship between BMI and PSA levels. Prostate 2011;71:1631-1.
[9]
D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-94.
[10]
Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360:1320-0.
[11]
Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hermandez J, Basler J, et al. The association of body mass index and prostate specific antigen in a population-based study. Cancer 2005;103:1092-2.
[12]
Ekman P. Genetic and environmental factors in prostate cancer genesis:identifying high-risk cohorts. Eur Urol 1999; 35:362-2.
[13]
Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Shuji I. Criteria and classification of obesity in Japan and Asia-Oceania. World Rev Nutr Diet 2005;94:1-12.
[14]
Stowell L, Sherman I, Hamel K. An enzyme-linked immunosorbent assay[ELISA] for prostate specific antigen. Forensic Sci Interm 1991;50:125-58.
[15]
Loeb S, Yu X, Nadler RB, Roehl KA, Han M, Hawkins SA, et al. Does body mass index affect preoperative prostate specific antigen velocity or pathological outcomes after radical prostatectomy? J Urol 2007;177:102-2.
[16]
Culp S, Porter M. The effect of obesity and lower prostatespecific antigen levels on prostate cancer screening results in American men. BJU Int 2009;104:1457-71.
[17]
Baillargeon J, Pollock BH, Kristal AR, Bradshaw P, Hernandez J, Basler J, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005;103:1092-2.
[18]
Kim YJ, Han BK, Hong SK, Byun SS, Kim WJ, Lee SE. Body mass index influences prostate-specific antigen in men younger than 60 years of age. Int J Urol. 2007;14:1009-92.
[19]
Yang WJ. The likelihood of having a serum PSA level of ≥2.5 or ≥4.0 ng/mL according to obesity in a screened Korean population. Asian J Androl 2013;15:770-0.
[20]
Naito M, Asai Y, Mori A, Fukada Y, Kuwabara M, Katase S, et al. Association of obesity and diabetes with serum prostatespecific antigen levels in Japanese males. Nagoya J Med Sci 2012;74:285-52.
[21]
Banez LL, Hamilton RJ, Partin AW, Vollmer RT, Sun L, Rodriguez C, et al. Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA 2007;298:2275-50.
[22]
Muller H, Raum E, Rothenbacher D, Stegmaier C, Brenner H. Association of diabetes and body mass index with levels of prostate-specific antigen:implications for correction of prostate-specific antigen cutoff values? Cancer Epidemiol Biomarkers Prev 2009;18:1350-0.
[23]
Thompson IM, Leach R, Troyer D, Pollock B, Naylor S, Higgins B. Relationship of body mass index and prostate specific antigen in a population-based study. Urol Oncol 2004;22:127-71.
[24]
Kang JS, Maygarden SJ, Mohler JL, Pruthi RS. Comparison of clinical and pathological features in African-American and Caucasian patients with localized prostate cancer. BJU Int 2004;93:1207-70.
Christopher Hartman, Nikhil Gupta, David Leavitt, David Hoenig, Zeph Okeke, Arthur Smith. Advances in percutaneous stone surgery[J]. Asian Journal of Urology, 2015, 2(1): 26
-32
.
